Glenmede Trust Co. NA Sells 29,374 Shares of Novo Nordisk A/S $NVO

Glenmede Trust Co. NA reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 18.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,387 shares of the company’s stock after selling 29,374 shares during the period. Glenmede Trust Co. NA’s holdings in Novo Nordisk A/S were worth $4,828,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $25,000. Scarborough Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $26,000. WealthCollab LLC grew its position in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the last quarter. Maseco LLP purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 6.2%

NVO opened at $44.16 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The stock has a market cap of $197.18 billion, a PE ratio of 10.37, a PEG ratio of 4.29 and a beta of 0.76. The business has a 50 day moving average of $46.96 and a 200-day moving average of $45.21.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q2 earnings exceeded expectations. Adjusted sales rose 7% at constant exchange rates to DKK 178.5 billion, while adjusted operating profit increased 11% to DKK 33.4 billion. Reported results were affected by a difficult comparison related to a U.S. 340B rebate provision reversal in the prior-year quarter. Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
• Positive Sentiment: Full-year guidance was raised. Novo Nordisk narrowed its expected decline in 2026 sales and operating profit, citing volume growth across its GLP-1 portfolio, demand for the higher-dose Wegovy injection and early traction for the oral Wegovy pill. Novo Nordisk’s Q2 profit beats forecasts, raises outlook
• Positive Sentiment: Oral Wegovy adoption is substantial. The pill reportedly surpassed 5 million U.S. prescriptions since launch, providing a potential new growth driver for Novo’s obesity franchise. Novo Nordisk Q2 2026 earnings beat, raises full-year outlook
• Neutral Sentiment: Novo is continuing a DKK 15 billion share-buyback program, which may support per-share results but does not address concerns about underlying demand. Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
• Neutral Sentiment: The company is studying potential thyroid-cancer risks among real-world GLP-1 users; the ongoing database research has not established a new safety signal. Novo Nordisk Probes Thyroid Cancer Risk in Real-World GLP-1 Users
• Negative Sentiment: Wegovy sales were viewed as a key miss. Investors appeared to expect stronger performance from the oral product, making the improved guidance insufficient to offset concerns about slowing injectable growth, pricing pressure and intensifying competition from Eli Lilly’s Mounjaro and Zepbound. Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes
• Negative Sentiment: Investor confidence also remains pressured after the recent failure of the zilte­vekimab ZEUS heart-disease trial, which increases reliance on the semaglutide franchise. Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Analyst Ratings Changes

A number of analysts recently commented on the company. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.